RE:RE:RE:RE:FSD Pharma updates recent
Mil_Man54 wrote: Talk is cheap Rosenberg...but the financials speak for themselves.....take a look at the last financial statement dated Nov 11, 2022.....
9 months ending 30 Sep 22
Salaries, benefits, bonuses and consulting fees 1,390,070
Share-based payments and bonuses 828,664
2,218,734
Total operating expenses 20,769,836
How much cash on hand Rosenberg....$40M or so.....no cash coming in....unsustainable expenses.....so you tell us how they'll have enough funds to finish a trial that will take years if not a decade?
nobody works for free
as long as milestones are reached and positive reflection on stock price and shareholder value is grown then I don't care as long as it's reasonable amounts
if it's $10,000,000 self serving package then it would be a red flag those rates and crazy
if it's within range of average corporate expenditure then I'm ok with it as long as they do what they say
and they have reached those milestones
options are restricted , so it Is what it is and another green day
let's hope good results from clinical trials showing efficacy